Haleon (HLN) Stock
NEW YORK STOCK EXCHANGE INC. · HLN
9.14
Fundamentals
Market cap
$40.72B
Price / Earnings ratio
18.3x
Price / Sales ratio
2.8x
Price / Book ratio
1.9x
Return on assets
N/A
Ex-Dividend date
14 Aug 2026
Last payment date
17 Sep 2026
Dividend amount
$0.12
Dividend yield
2.03%
Debt / Equity ratio
N/A
Recent news

Proactive Investors
Haleon tipped to cut sales growth guidance as cough and cold season clouds outlook
NeutralHLNSeptember 25, 2026
Proactive InvestorsNeutral
Haleon tipped to cut sales growth guidance as cough and cold season clouds outlook
HLN

Proactive Investors
Deutsche Bank stays bearish on Haleon as growth headwinds mount
NeutralHLNSeptember 23, 2026
Proactive InvestorsNeutral
Deutsche Bank stays bearish on Haleon as growth headwinds mount
HLN

Reuters
Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs
NeutralHLNSeptember 16, 2026
ReutersNeutral
Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs
HLN

Zacks Investment Research
LCUT or HLN: Which Is the Better Value Stock Right Now?
NeutralHLNSeptember 11, 2026
Zacks Investment ResearchNeutral
LCUT or HLN: Which Is the Better Value Stock Right Now?
HLN
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy0
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
18B12B6B0
Debt & Balance Sheet
Total assets
Total liabilities
2025
39B26B13B0
Revenue to Profit
2025$14.9B
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$1.7B
Net incomeEarnings
EPS forecast
Actual EPS
$0.23
FYFY24
$0.11
H1FY24
FYFY25
$0.12
H1FY25
The company reported results on Jul 31 2025. The market has no earnings per share expectations for this quarter.
% positive news of 10 articles
published over the past 14 days
Latest news

Proactive Investors
Haleon tipped to cut sales growth guidance as cough and cold season clouds outlook
NeutralHLNSeptember 25, 2026
Proactive InvestorsNeutral
Haleon tipped to cut sales growth guidance as cough and cold season clouds outlook
HLN

Proactive Investors
Deutsche Bank stays bearish on Haleon as growth headwinds mount
NeutralHLNSeptember 23, 2026
Proactive InvestorsNeutral
Deutsche Bank stays bearish on Haleon as growth headwinds mount
HLN

Reuters
Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs
NeutralHLNSeptember 16, 2026
ReutersNeutral
Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs
HLN

Zacks Investment Research
LCUT or HLN: Which Is the Better Value Stock Right Now?
NeutralHLNSeptember 11, 2026
Zacks Investment ResearchNeutral
LCUT or HLN: Which Is the Better Value Stock Right Now?
HLN

Proactive Investors
Deutsche Bank expects European consumer staples to underperform as structural pressures mount
NeutralHLNSeptember 9, 2026
Proactive InvestorsNeutral
Deutsche Bank expects European consumer staples to underperform as structural pressures mount
HLN

Reuters
Haleon secures better shelf space at Walmart, Target in bid to boost market share
NeutralHLNSeptember 3, 2026
ReutersNeutral
Haleon secures better shelf space at Walmart, Target in bid to boost market share
HLN

Zacks Investment Research
LCUT vs. HLN: Which Stock Is the Better Value Option?
NeutralHLNAugust 26, 2026
Zacks Investment ResearchNeutral
LCUT vs. HLN: Which Stock Is the Better Value Option?
HLN

Proactive Investors
Jefferies raises Haleon price target to 410p on margin strength
NeutralHLNAugust 24, 2026
Proactive InvestorsNeutral
Jefferies raises Haleon price target to 410p on margin strength
HLN

Zacks Investment Research
ACCO vs. HLN: Which Stock Is the Better Value Option?
NeutralHLNAugust 4, 2026
Zacks Investment ResearchNeutral
ACCO vs. HLN: Which Stock Is the Better Value Option?
HLN

Reuters
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US
NeutralHLNJuly 30, 2026
ReutersNeutral
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US
HLN
About Haleon
Haleon is a world-leading company focused on everyday health. It is the new name of GSK’s spun out Consumer Healthcare division. Haleon's leading brands are built on science, innovation and human understanding and are trusted by millions of consumers globally. Its current portfolio includes various international brands including Sensodyne, Voltaren and Panadol.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees24,535
CEOMr. Brian James McNamara
IPO DateJul 22, 2022
HeadquartersWeybridge, United Kingdom
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Brian James McNamara | CEO & Executive Director | 1966 |
| Ms. Dawn Amanda Allen | CFO & Director | 1968 |
| Ms. Claire Dickson | Chief Digital & Technology Officer | — |
| Ms. Joanne Russell | Head of Investor Relations | — |
| Mr. Adrian Charles Morris | General Counsel | 1967 |
| Ms. Tamara Jane Rogers | Chief Marketing Officer | 1968 |
| Ms. Line De Decker | Chief Human Resources Officer | 1974 |
| Mr. Filippo Lanzi | President of EMEA & LatAm | — |
| Mr. Keith Choy | President of Asia Pacific | 1969 |
| Mr. Bjorn Timelin | Head of Strategy | — |
Fundamentals
Valuation
Market cap$40.72B
Price-to-sales ratio2.77
Price-to-book value1.89
Price-earnings ratio18.30
Return on EquityN/A
Return on SalesN/A
Return on AssetsN/A
PEG ratio2.15
Earnings Per Share
Earnings Per Share$0.50
Income Statement
Average volume17,661,760
EBITDA$3.57B
1 year high (52w)$11.28
1 year low (52w)$8.65
Dividend
Ex dividend date14 Aug 2026
Dividend amount$0.12
Dividend yield2.03%
Last payment date17 Sep 2026
Dividend yield (TTM)2.08%
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
0 Wall Street Analyst Ratings
N/A
0% Buy
0% Hold
0% Sell
Target price
$0.00
Est return
0.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | -6.3 | -18.9 | +5.0 | -0.3 | +12.2 | +13.0 | ||||||
| 2023 | +2.1 | -1.0 | +2.8 | +8.6 | -9.0 | +2.8 | +7.6 | -3.9 | +2.8 | -2.2 | +5.2 | -4.1 |
| 2024 | -0.4 | +1.9 | +0.5 | +2.3 | +1.1 | -2.5 | +10.0 | +9.1 | +4.1 | -9.4 | -0.7 | -1.3 |
| 2025 | +0.3 | +7.4 | -2.7 | -0.3 | +9.9 | -9.1 | -8.9 | +1.4 | -8.1 | +2.9 | +4.3 | +3.2 |
| 2026 | +4.7 | +4.8 | -7.9 | -7.3 | -3.4 | +5.5 | +5.0 | +2.3 | -8.0 |
Corporate actions
Upcoming
No upcoming corporate actions for HLN
Past
DividendQ3/26
Ex-dividend date14 Aug 2026
Payable date17 Sep 2026
Amount per share$0.06
DividendQ2/26
Ex-dividend date10 Apr 2026
Payable date14 May 2026
Amount per share$0.13
DividendQ3/25
Ex-dividend date15 Aug 2025
Payable date18 Sep 2025
Amount per share$0.06
DividendQ2/25
Ex-dividend date25 Apr 2025
Payable date5 Jun 2025
Amount per share$0.12
DividendQ3/24
Ex-dividend date16 Aug 2024
Payable date19 Sep 2024
Amount per share$0.05
DividendQ1/24
Ex-dividend date14 Mar 2024
Payable date16 May 2024
Amount per share$0.11
DividendQ3/23
Ex-dividend date24 Aug 2023
Payable date5 Oct 2023
Amount per share$0.05
DividendQ1/23
Ex-dividend date16 Mar 2023
Payable date27 Apr 2023
Amount per share$0.06



